



May 19, 2026

BSE Limited

P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Scrip Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Press Release – Q4FY26 & FY26

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith the Press Release on Financial Results of the Company for the quarter and financial year ended on March 31, 2026.

The above-mentioned Press Release is also being uploaded on the website of the company i.e. www.mankindpharma.com.

You are requested to kindly take the above information on your records.

Thanking You,

Yours Faithfully,


For **Mankind Pharma Limited**

Hitesh Kumar Jain
Company Secretary &
Compliance Officer

Encl.: A/a

Mankind Pharma revenue up by 11.8%; Adj. EBITDA margin at 27.1% in Q4FY26

New Delhi, India, 19 May, 2026: Mankind Pharma (BSE: 543904 | NSE: MANKIND) India's fourth largest pharmaceutical Company today announced its financial results for the fourth quarter and full year ended 31st March 2026. The information mentioned in this release is based on consolidated financial statements.



Mr. Rajeev Juneja – Vice Chairman & Managing Director

- Revenue increased ~12% YoY with adj. EBITDA margins¹ of 27.1%
- Overall domestic business (ex CH) grew by ~13% led by:
 - ✓ double digit growth in Mankind domestic business led by 14.7% in cardiac and 11.6% in anti-diabetes (120 bps YoY increase in chronic share to ~40%)
 - ✓ sequential growth recovery in key acute therapies like Gastro, VMN, etc.
 - ✓ strong double digit growth in BSVs domestic business
- OTC business grew by 20% led by strong growth in e-commerce; International business witnessed muted growth due to geo-political headwinds
- We are on track in strengthening scale and advancing specialization through four key pillars - steady base business, fast growing specialty chronic, high potential OTC business, and super specialty BSV portfolio to deliver long-term sustainable growth.

1. Adjusted with one time impact of labour code regulations and other non-recurring cost (Refer note 10 of Consolidated Financial Results)

Press Release

Q4 FY26 Performance Summary

- Revenue from Operations at INR 3,443 Cr, up by 11.8% YoY
 - Domestic revenue at INR 2,886 Cr, up 13.4%, Exports at INR 557 Cr, up 4.2% YoY
- Adjusted EBITDA margin of 27.1%, up by 400 bps YoY and PAT margin of 16.2%, up 230 bps YoY
- Diluted EPS¹ of INR 13.4, up 30.3% YoY (FV Re.1)

1. Diluted EPS not annualised

FY26 Performance Summary

- Revenue from Operations at INR 14,278 Cr, up by 17.0% YoY
 - Domestic revenue at INR 12,217 Cr, up 14.4%, Exports at INR 2,061 Cr, up 34.5% YoY
- Adjusted EBITDA margin of 25.4% and PAT margin of 13.6%
- Diluted EPS¹ of INR 46.3 down by 5.7% YoY (FV Re.1)
- CFO to EBITDA ratio was 89% for FY26 vs 80% in FY25

1. Diluted EPS not annualised

Domestic Business¹

- Domestic revenue² increased 13% YoY driven by double digit growth in Mankind business, supported by strong growth in BSV specialty business
- Secondary sales growth of 8.7% vs 10.7% IPM³ in Q4FY26 – primarily due to
 - strong performance in chronic growth supported by 14.7% in Cardiac and 11.6% in Anti-Diabetes
 - muted growth in anti-infectives partially offset by sequential recovery in Gastro, VMN, Derma etc.
- Strong growth in key focused brands:
 - outperformance in key acute brands like Cefakind-CV (1.3x), Nurokind-LC (1.1x), Pantakind (1.4x), Dydroboon (1.9x) etc in Q4FY26
 - c.16.5% growth in Telmikind family; 23.7% in Lipirose; 28.7% in Statpure in cardiac during Q4FY26
 - Glizid brand family crossed Rs 230 Cr in MAT Mar'26 (35%+ growth)
- Healthy growth in BSVs key brands - Foligraf (52%), HMG (40%), Ossopan (72%), Lactare (46%) and Anti-D having 100% market share has grown 10%
- Consistently maintained #1 rank over last 9 years with prescription share of 15.1%

1. As per IQVIA March-2026 // 2. Denotes reported number // 3. Ex-GLP1 - innovator

Consumer Healthcare Business¹

- Revenue² growth of 20% YoY in Q4FY26 primarily driven by strong growth in Manforce, Prega News, Gasofast and Nimulid
- MT & E-Com share increased to 13% in FY26 as compared to 9% in FY25 supported by 57% growth
- Healthy growth in secondary sales² for Gas-o-fast, Prega News and Ova news of 24%, 28% and 65% YoY respectively in Q4FY26

1. As per IQVIA / IQVIA Retail, March-2026 // 2. Denotes reported number

Press Release

Exports

- Revenue from International business witnessed muted growth of 4% YoY in Q4FY26 impacted due to geo-political headwinds
- Mankind (excluding BSV) has launched 4 new products in FY26 taking the total launched products to 48 in US

Consolidated Profit & Loss Account

In INR Crore	Q4 FY26	Q4 FY25	YoY%	Q3 FY26	QoQ%
Revenue from Operations	3,443	3,079	11.8%	3,567	-3.5%
<i>Gross Margins %</i>	<i>72.2%</i>	<i>71.6%</i>	<i>60 bps</i>	<i>72.6%</i>	<i>(40 bps)</i>
EBITDA	910	686	32.7%	816	11.5%
<i>EBITDA Margin %</i>	<i>26.4%</i>	<i>22.3%</i>	<i>410 bps</i>	<i>22.9%</i>	<i>350 bps</i>
Adjusted EBITDA	933 ¹	711 ²	31.1%	923 ¹	0.8%
<i>Adjusted EBITDA Margin %</i>	<i>27.1%¹</i>	<i>23.1%²</i>	<i>400 bps</i>	<i>25.9%¹</i>	<i>120 bps</i>
PAT	559	429	30.4%	414	35.2%
<i>PAT Margin %</i>	<i>16.2%</i>	<i>13.9%</i>	<i>230 bps</i>	<i>11.6%</i>	<i>460 bps</i>

1. Adjusted with one time impact of labour code regulations and other non-recurring cost (Refer note 10 of Consolidated Financial Results)

2. Adjusted with one time M&A related expenses & other non-recurring cost

In INR Crore	FY26	FY25	YoY%
Revenue from Operations	14,278	12,207	17.0%
<i>Gross Margins %</i>	<i>71.6%</i>	<i>71.4%</i>	<i>20 bps</i>
EBITDA	3,499	3,030	15.5%
<i>EBITDA Margin %</i>	<i>24.5%</i>	<i>24.8%</i>	<i>(30 bps)</i>
Adjusted EBITDA	3,629 ¹	3,159 ²	14.9%
<i>Adjusted EBITDA Margin%</i>	<i>25.4%¹</i>	<i>25.9%²</i>	<i>(50 bps)</i>
PAT	1,938	2,007	-3.4%
<i>PAT Margin %</i>	<i>13.6%</i>	<i>16.4%</i>	<i>(280 bps)</i>
Diluted EPS (INR)	46.3	49.1	-5.7%
Cash EPS (INR)	68.1	64.4	5.6%

1. Adjusted with one time impact of labour code regulations and other non-recurring cost (Refer note 10 of Consolidated Financial Results)

2. Adjusted with one time M&A related expenses & other non-recurring cost

Segmental Revenue Break Up

In INR Crore	Q4 FY26	Q4 FY25	YoY%	Q3 FY26	QoQ%
Domestic	2,886	2,544	13.4%	3,046	-5.3%
• Domestic (Ex-CH)	2,673	2,366	12.9%	2,843	-6.0%
• Consumer Healthcare (CH)	213	178	19.8%	203	5.0%
Exports	557	535	4.2%	521	7.0%
Total	3,443	3,079	11.8%	3,567	-3.5%

In INR Crore	FY26	FY25	YoY%
Domestic	12,217	10,675	14.4%
• Domestic (Ex-CH)	11,338	9,866	14.9%
• Consumer Healthcare (CH)	879	809	8.7%
Exports	2,061	1,532	34.5%
Total	14,278	12,207	17.0%

Earning concall Details

Date	20th MAY, 2026
Time	12:00 pm – 01:00 pm IST
Zoom Link	Click here

About Mankind Pharma

Mankind Pharma (BSE: 543904 | NSE: MANKIND) is one of the largest pharmaceutical company in India, which focuses on the domestic market with its Pan India presence. Mankind operates at the intersection of the Indian pharmaceutical formulations and consumer healthcare sectors with the aim of providing quality products at affordable prices. The company is a leading player in the domestic pharmaceuticals business present across acute and chronic therapeutic areas including anti-infectives, cardiovascular, gastrointestinal, antidiabetic, neuro/CNS, gynaecology, VMN and respiratory, among others with a strategy to increase chronic presence going ahead. In the consumer healthcare business, the company operates in the condoms, pregnancy detection, emergency contraceptives, antacid powders, vitamin and mineral supplements and anti-acne preparations categories, among others, with several category-leading brands. Following the acquisition of BSV, Mankind Pharma has further strengthened its leadership in the domestic women's health segment. Mankind's distribution network includes a robust field force of 18,500+ professionals, and a reach extending to over five lakh doctors across urban and rural markets. The company has 32 manufacturing facilities in India manufacturing a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow fill seal, soft and hard gels, eye drops, creams, contraceptives and other over-the-counter products. Mankind has a consistent track record of product innovation through 7 dedicated R&D facilities backed by more than 750 scientists.

For more information, visit www.mankindpharma.com



Press Release

Safe Harbour Statement

The statements, are as on date and may contain forward-looking statements like the words “believe”, “expects”, “anticipate”, “aim”, “will likely result”, “Would”, “will continue”, “contemplate” “intends”, “plans”, “estimates”, “seek to”, “future”, “objective”, “projects”, “goal”, “likely”, “Project”, “should”, “potential” “will”, “may”, “targeting” or other words of similar expressions/ meaning regarding the financial position, business strategy, plans, targets and objectives of the Company. Such forward-looking statements involve known and unknown risks which may cause actual results, performance or achievements to be materially different from the results or achievements expressed or implied. The risks and uncertainties inter-alia, relating to these statements include (i) cash flow projections, (ii) industry and market conditions; (iii) ability to manage growth; (iv) competition; (v) government policies and regulations; (vi) obtaining regulatory approvals; (vii) domestic & international economic conditions such as interest rate & currency exchange fluctuations; (viii) political, economic, legal and social conditions in India/ elsewhere; (ix) technological advances; (x) claims and concerns about product safety and efficacy; (xi) domestic and foreign healthcare reforms; (xii) inability to build production capacity; (xiii) unavailability of raw materials and failure to gain market acceptance.

The Company and its subsidiaries shall not have any responsibility or liability whatsoever for any loss howsoever arising from this presentation or its contents or otherwise arising in connection therewith. Also, Company assume no responsibility to publicly amend, modify or revise any forward looking statements, on the basis of any subsequent developments, information or events, or otherwise.

For Queries Contact

Mankind Pharma - Investor Relations & Strategy

Abhishek Agarwal

Email address: investors@mankindpharma.com

Contact Number: +91-11-46846700

Mankind Pharma - Corporate Communication

Natasha Raj

Email address: natasha.raj@mankindpharma.com

Contact Number: 011-46846700 Ext: 3201

Adfactors PR - Investor Relations / Public Relations

Smit Shah / Apoorva Sharma

Email address: smit.shah@adfactorspr.com / apoorva.sharma@adfactorspr.com

Contact Number: +91 9870789596 / +91 9999739452